ReviewFrontiers in neurology2025
Blood-based biomarkers and neuroimaging for early detection of post-stroke cognitive impairment: current evidence and synergistic prospects.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Acute-phase serum metabolomics signatures for predicting post-stroke cognitive impairment after ischemic stroke: a prospective cohort study.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Blood-Based Biomarkers for Post-Stroke Cognitive Impairment.Current issues in molecular biology · 2026Review
- The XGBoost Model Versus the Logistic Regression Model Created Based on Serum Markers in Predicting the Risk of Post-Stroke Cognitive Impairment Following Acute Ischemic Stroke.Brain and behavior · 2026Article
- Dynamic trajectories of inflammatory biomarkers and post-stroke cognitive impairment: a comprehensive review of neuroimmune mechanisms, longitudinal modeling, and clinical translation.Frontiers in neurology · 2026Review
- Correlation between blood biomarkers and post-stroke cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Mapping the landscape of MRI research in post-stroke cognitive impairment: A bibliometric analysis from 2000 to 2026.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post stroke cognitive impairment (PSCI) is a series of common complications caused by stroke, ranging from mild cognitive impairment to dementia, which seriously affects the recovery and living quality of patients. Currently, the diagnosis of PSCI in the clinic mostly relies on subjective scale assessment, the untimeliness and imprecision of results greatly limit the efficient identification as well as the subsequent diagnosis and treatment of PSCI. With the increasing popularity and optimization of bioassay techniques and equipment, more and more studies have identified potential early warning markers of stroke patients with the development of their cognitive deficits through hematological testing or imaging. Therefore, the application of blood-based biomarkers and imaging techniques is important for the early identification of PSCI. This review focuses on the research progress of the above two testing modalities in PSCI to discuss their vital meanings for disease recognition. It also suggests that the combined application of the two is expected to improve the potential value of early and accurate diagnosis, with a view to providing new ideas for the clinical diagnosis and treatment of PSCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.